Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Acorda Therapeutics, Inc. (ACOR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.6100+0.0900 (+3.57%)
At close: 04:00PM EST
Advertisement
Sign in to post a message.
  • B
    Bruce
    Considered that it only has a market cap of 41 million,the risk/reward ratio is pretty good on this one.If they can ever get Inbrija going or license out the Inhalation technology,it could be a big winner.If not ,you have a nice tax loss write off
    Neutral
  • E
    EAR
    15.Nov SEC Filing Ron Cohen insider buy
    100000 Option Exercise at 3,64US$

    only up we go for sure
  • Y
    Yahoo Finance Insights
    Acorda Therapeutics reached a 52 Week low at 2.51
  • E
    EAR
    Ro should put ACOR for sale... what we can get for every share ? I presume >6$
  • E
    EAR
    I am very sad about the price action. Why is the share price going down?Germany is a huge market for INBRIJA..Hoping for a buyout...Acorda Therapeutics Announces Agreement to Commercialize INBRIJA� in GermanyExplore the topics mentioned in this article#$%$5 million upfront paymentSignificant double-digit percent of selling price for supplyAdditional sales-based milestonesCommercial launch expected mid-2022
  • Y
    Yahoo Finance Insights
    Acorda Therapeutics reached a 52 Week low at 2.61
  • Y
    Yahoo Finance Insights
    Acorda Therapeutics reached an all time low at 2.49
  • R
    Rainer
    Will this now finally go to zero?
    Well, I don't have too much in this.
    Sometimes you lose.

    What do you guys think?
  • Y
    Yahoo Finance Insights
    Acorda Therapeutics is up 7.30% to 2.79
  • R
    ROB TOM
    MC dislocated from value of company. It's now just simple math associated with share payment of interest due Dec. 1.
  • L
    Lawrence C
    You're going to have flush twice to get rid of thie huge log.
  • R
    ROB TOM
    Did you guys not see the Germany partnership news?
    Bullish
  • L
    Lawrence C
    I smell reverse split...how about 100 to 1..?
  • R
    ROB TOM
    $ADMS conversation
    If you are looking for a similar small cap player in the micro cap Parkinson's field with released products and higher revenue trading at 50m check out $ACOR. This comp is pushing it higher today but still way under valued when considering this deal, which I think is too cheap for $ADMS. Wouldnt be surprised by a competitive counter.
    Bullish
  • m
    martin
    Back to even on CLOV oh well, I’ll wait it out. As for you EAR are you ready for your
  • L
    Lawrence C
    Repent you heathens. The End is Near.
  • m
    martin
    Looks good but Ameritrade is posting a loss of 2.43.
  • g
    gochenauer
    (http://Rightpicker.com) is a must for any trader. Their watchlist which covers pre-market movers is one of the best researched in the industry. I don’t start trading without reading their daily email each morning!
  • A
    Andreas
    what will happen on Monday?
  • C
    Champagne
    If anybody cares...
    We are encouraged by the 24% increase in INBRIJA net sales over the second quarter, even with the challenges posed by the second wave of COVID-19. We are also pleased that coverage for INBRIJA continued to increase during the quarter, with over 96% of commercially-insured patients now having access to it," said Ron Cohen, M.D., Acorda's President and Chief Executive Officer. "In addition, AMPYRA's performance and the milestone payment we received for FAMPYRA have further strengthened our financial position. We are also continuing our work to reduce operating costs and monetize excess capacity at our Chelsea facility, to help drive long-term value for all shareholders.
Advertisement
Advertisement